Understanding the mechanisms underlying melanoma resistance, such as alterations in genes and signaling pathways, including the MAPK and PI3K/AKT pathways, is crucial to tackling the MDR of melanoma [22,24,26,29–36]. This evidence concerns the gene AKT1 and melanoma.